National Vision (EYE)
(Delayed Data from NSDQ)
$15.78 USD
-0.23 (-1.44%)
Updated May 17, 2024 04:00 PM ET
After-Market: $15.76 -0.02 (-0.13%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$15.78 USD
-0.23 (-1.44%)
Updated May 17, 2024 04:00 PM ET
After-Market: $15.76 -0.02 (-0.13%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth D Momentum A VGM
Zacks News
CVS Health (CVS) Gains From Digitalization, Hurt by Seasonality
by Zacks Equity Research
CVS Health's (CVS) consumer-centric digital strategy is now more relevant in the current environment as people are using technology while staying indoors.
Here's Why You Should Add Phibro (PAHC) to Your Portfolio
by Zacks Equity Research
Investors are optimistic about Phibro (PAHC) on solid third-quarter performance and potential in emerging markets.
Bruker's (BRKR) Research Tools Enable New insight on PACS
by Zacks Equity Research
Bruker's (BRKR) quantitative NMR and MS assay platform together with Australian National Phenome Centre evaluate risk and longitudinal monitoring of post-acute COVID-19 syndrome.
Cardiovascular Systems (CSII) Coronary Arm Grows, Margin Dips
by Zacks Equity Research
Cardiovascular Systems (CSII) is progressing well with its objective to introduce OAS globally.
Cardiovascular Systems (CSII) Coronary OAS Study Data Favorable
by Zacks Equity Research
Cardiovascular Systems' (CSII) Diamondback 360 Coronary OAS helps in restoring native vessel compliance, simplify procedural workflow and enhance percutaneous coronary intervention outcomes.
Medtronic (MDT) Reveals Promising Results From Evolut Trial
by Zacks Equity Research
The Low Risk Trial has demonstrated non-inferiority of Medtronic's (MDT) TAVR system over open heart surgery.
LabCorp's (LH) New Bioanalytical Lab to Boost APAC Operation
by Zacks Equity Research
The new laboratory by LabCorp (LH) is set to enable faster data turnaround for early phase trials in Asia-Pacific markets.
Thermo Fisher (TMO) to Boost Cell Therapies With UCSF Deal
by Zacks Equity Research
Thermo Fisher's (TMO) collaboration with UCSF will enable end-to-end solution to accelerate cell therapy development and manufacturing with new facility.
EYE or SRDX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
EYE vs. SRDX: Which Stock Is the Better Value Option?
STERIS (STE) Q4 Earnings Fall Shy of Estimates, FY22 View Up
by Zacks Equity Research
STERIS' (STE) fourth-quarter 2021 revenues improved year over year on robust growth across three segments.
TeleFlex (TFX) Urolift Grows, Organic Sales Hit by Pandemic
by Zacks Equity Research
On the strength of a successful 2020 campaign, Teleflex (TFX) doubles the awareness for UroLift in the targeted population of men with BPH.
LabCorp's (LH) Pixel Kit Gets EUA for Younger Population
by Zacks Equity Research
LabCorp (LH) becomes the first major commercial laboratory to offer a COVID-19 PCR Test Home Collection Kit for children and adolescents.
Abbott (ABT) Receives CE Mark for Latest Navitor TAVI System
by Zacks Equity Research
Abbott's (ABT) latest-generation Navitor TAVI system features improvements to reduce or eliminate a backflow of blood around valve implants.
Here's Why You Should Buy Henry Schein (HSIC) Stock Now
by Zacks Equity Research
Investors are optimistic about Henry Schein (HSIC) on solid first-quarter performance and strategic deals.
Medtronic's (MDT) Coronary Market Share Grows Amid Pandemic
by Zacks Equity Research
In Gastrointestinal, Medtronic (MDT) is witnessing some modest share gains, driven in part by its partnership with the NHS in England.
National Vision (EYE) Q1 Earnings Top Estimates, View Up
by Zacks Equity Research
According to National Vision (EYE), increased demand for low-cost eye exams, glasses and contact lenses boosts first-quarter performance.
Here's Why You Should Hold on to Tandem Diabetes (TNDM) Now
by Zacks Equity Research
Investors continue to be optimistic about Tandem Diabetes (TNDM) on strong quarterly results and robust pump sales.
National Vision (EYE) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
National Vision (EYE) delivered earnings and revenue surprises of 45.45% and 3.14%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Tandem (TNDM) Global Growth Strong, Costs Continue to Rise
by Zacks Equity Research
Tandem Diabetes (TNDM) is witnessing high international demand for the t:slim X2 pump.
Here's Why You Should Add Bruker (BRKR) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Bruker (BRKR) on its slew of product launches and potential in the BSI Nano Group.
Here's Why You Should Buy Amedisys (AMED) Stock Now
by Zacks Equity Research
Investors are optimistic about Amedisys (AMED) on bright Personal Care prospects, and strategic acquisitions and partnerships.
Bull of the Day: National Vision (EYE)
by Kevin Cook
As a nation, optical care needs are rising and re-opening trends are spurring a big catch-up on exams
Aurora Cannabis (ACB) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Aurora Cannabis' (ACB) sturdy consumer cannabis sales are likely to have benefited its performance in the fiscal third quarter.
Here's Why You Should Hold on to Illumina (ILMN) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Illumina (ILMN), backed by its focus on partnerships and robust adoption of its products.
Here's Why You Should Hold on to ResMed (RMD) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about ResMed (RMD), owing to its potential in digital health and consistent high demand for its masks.